Anne Herman1,2, Caroline Peeters1, Alexia Verroken3, Isabelle Tromme1, Dominique Tennstedt1, Liliane Marot1,4, Claire Dachelet4, Damien Gruson5, Cedric Hermans6, Marie Baeck1,2. 1. Department of Dermatology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. 2. Pneumology, ENT, and Dermatology Pole, Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium. 3. Department of Laboratory Medicine, Division of Microbiology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. 4. Department of Anatomopathology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. 5. Department of Laboratory Medicine, Division of Clinical Biochemistry, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. 6. Department of Internal Medicine, Division of Hematology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Abstract
Importance: During the coronavirus disease 2019 (COVID-19) pandemic, several cases of chilblains have been reported. Objective: To determine if chilblains are associated with COVID-19. Design, Setting, and Participants: This monocentric case series was conducted at the Department of Dermatology at Cliniques universitaires Saint-Luc, a tertiary care hospital in Brussels, Belgium, between April 10 and April 17, 2020. We evaluated a total of 31 referred patients who had recently developed chilblains. Main Outcomes and Measures: Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA on nasopharyngeal swabs for all patients and in skin biopsy specimens for 22 patients. Blood samples from all patients were tested for specific anti-SARS-CoV-2 immunoglobulin (Ig) M and IgG antibodies. All patients had extended blood analyses. Histologic (22 patients) and immunofluorescence examinations (15 patients) were performed on the skin biopsy specimens. Results: The 31 patients were generally in good health; most were teenagers or young adults, and 19 were women. Histopathologic analysis of skin biopsy specimens (22 patients) confirmed the diagnosis of chilblains and showed occasional lymphocytic or microthrombotic phenomena. Immunofluorescence analyses showed vasculitis of small-diameter vessels in 7 patients. In all patients, SARS-CoV-2 RNA remained undetected by RT-PCR on nasopharyngeal swabs and in biopsy samples of the skin lesions. The IgM and IgG antibody titers were negative for SARS-CoV-2 in all patients (<1.0 arbitrary unit/mL). No significant abnormalities in blood test results were suggestive of systemic disease. Antinuclear antibody titers were low in 7 patients and higher in 1 patient. Conclusions and Relevance: Chilblains appeared not to be directly associated with COVID-19 in this case series. Lifestyle changes associated with community containment and lockdown measures are a possible explanation for these lesions.
Importance: During the coronavirus disease 2019 (COVID-19) pandemic, several cases of chilblains have been reported. Objective: To determine if chilblains are associated with COVID-19. Design, Setting, and Participants: This monocentric case series was conducted at the Department of Dermatology at Cliniques universitaires Saint-Luc, a tertiary care hospital in Brussels, Belgium, between April 10 and April 17, 2020. We evaluated a total of 31 referred patients who had recently developed chilblains. Main Outcomes and Measures: Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA on nasopharyngeal swabs for all patients and in skin biopsy specimens for 22 patients. Blood samples from all patients were tested for specific anti-SARS-CoV-2 immunoglobulin (Ig) M and IgG antibodies. All patients had extended blood analyses. Histologic (22 patients) and immunofluorescence examinations (15 patients) were performed on the skin biopsy specimens. Results: The 31 patients were generally in good health; most were teenagers or young adults, and 19 were women. Histopathologic analysis of skin biopsy specimens (22 patients) confirmed the diagnosis of chilblains and showed occasional lymphocytic or microthrombotic phenomena. Immunofluorescence analyses showed vasculitis of small-diameter vessels in 7 patients. In all patients, SARS-CoV-2 RNA remained undetected by RT-PCR on nasopharyngeal swabs and in biopsy samples of the skin lesions. The IgM and IgG antibody titers were negative for SARS-CoV-2 in all patients (<1.0 arbitrary unit/mL). No significant abnormalities in blood test results were suggestive of systemic disease. Antinuclear antibody titers were low in 7 patients and higher in 1 patient. Conclusions and Relevance: Chilblains appeared not to be directly associated with COVID-19 in this case series. Lifestyle changes associated with community containment and lockdown measures are a possible explanation for these lesions.
Authors: X H Yao; T Y Li; Z C He; Y F Ping; H W Liu; S C Yu; H M Mou; L H Wang; H R Zhang; W J Fu; T Luo; F Liu; Q N Guo; C Chen; H L Xiao; H T Guo; S Lin; D F Xiang; Y Shi; G Q Pan; Q R Li; X Huang; Y Cui; X Z Liu; W Tang; P F Pan; X Q Huang; Y Q Ding; X W Bian Journal: Zhonghua Bing Li Xue Za Zhi Date: 2020-05-08
Authors: Y Zhang; W Cao; M Xiao; Y J Li; Y Yang; J Zhao; X Zhou; W Jiang; Y Q Zhao; S Y Zhang; T S Li Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2020-04-14
Authors: V Piccolo; I Neri; C Filippeschi; T Oranges; G Argenziano; V C Battarra; S Berti; F Manunza; A B Fortina; V Di Lernia; V Boccaletti; G De Bernardis; B Brunetti; C Mazzatenta; A Bassi Journal: J Eur Acad Dermatol Venereol Date: 2020-05-15 Impact factor: 6.166
Authors: Diego Fernandez-Nieto; Juan Jimenez-Cauhe; Ana Suarez-Valle; Oscar M Moreno-Arrones; David Saceda-Corralo; Arantxa Arana-Raja; Daniel Ortega-Quijano Journal: J Am Acad Dermatol Date: 2020-04-24 Impact factor: 11.527
Authors: S Recalcati; T Barbagallo; L A Frasin; F Prestinari; A Cogliardi; M C Provero; E Dainese; A Vanzati; F Fantini Journal: J Eur Acad Dermatol Venereol Date: 2020-05-27 Impact factor: 6.166
Authors: Ricardo Pasquini Neto; Felipe Antonio Torres Mazzo; Fernanda de Almeida Vieira; Gustavo de Souza Bueno; João Vitor Correa Previdi; Lara Rozetti da Silva; Nasthia Kreuz Baziulis da Silva; Joseph Lucius Jorizzo; Felipe Bochnia Cerci Journal: Rev Paul Pediatr Date: 2022-06-10
Authors: P Moghadam; L Frumholtz; L Jaume; A De Masson; M Jachiet; E Begon; L Sulimovic; A Petit; H Bachelez; M Bagot; J-D Bouaziz; C Cassius Journal: J Eur Acad Dermatol Venereol Date: 2021-06-19 Impact factor: 9.228
Authors: A Barrera-Godínez; S Méndez-Flores; M Gatica-Torres; A Rosales-Sotomayor; K I Campos-Jiménez; D M Carrillo-Córdova; M C Durand-Muñoz; G L Mena-Hernández; Y K Melchor-Mendoza; A L Ruelas-Villavicencio; A García-Irigoyen; G A Acatitla-Acevedo; S Toussaint-Caire; J Domínguez-Cherit Journal: J Eur Acad Dermatol Venereol Date: 2021-06-07 Impact factor: 9.228
Authors: Marta Bascuas-Arribas; David Andina-Martinez; Juan Añon-Hidalgo; Jose Antonio Alonso-Cadenas; Angela Hernandez-Martin; Nuria Lamagrande-Casanova; Lucero Noguero-Morel; Ana Mateos-Mayo; Isabel Colmenero-Blanco; Antonio Torrelo Journal: Pediatr Dermatol Date: 2022-02-07 Impact factor: 1.997
Authors: G Brancaccio; N Gussetti; L Sasset; M Alaibac; M Tarantello; R Salmaso; M Trevenzoli; A M Cattelan Journal: Pathog Glob Health Date: 2021-03-17 Impact factor: 2.894